register

News & Trends - MedTech & Diagnostics

Demand for cancer surgery set to surge

Health Industry Hub | January 27, 2021 |

MedTech News: A new modelling study led by UNSW predicts demand for cancer surgery will rise by 52% within two decades, with low-income countries bearing the greatest burden. 

Public health researchers, led by UNSW Sydney, have estimated the number of cancer cases requiring surgery globally each year, predicting the number will rise from 9.1 million to 13.8 million from 2018 to 2040 – an increase of 52% or 4.7 million cases.

Their research shows the greatest relative increase will occur in 34 low-income countries, where the number of cases requiring surgery is expected to more than double by 2040 (314,355 cases to 650,164, or 107%).

The modelling studypublished in The Lancet Oncology on Friday, analysed global demand for cancer surgery and estimated surgical and anaesthesia workforce requirements between 2018 and 2040.

Lead author Dr Sathira Perera, a UNSW Scientia PhD scholar, said an absence of evidence-based estimates of future demand had restricted efforts to improve cancer care around the world.

Cancer is a leading cause of death and disability globally, and has substantial economic impacts, with recent evidence suggesting a disproportionate burden of disease in low- and middle-income countries.

“Our analysis has revealed that, in relative terms, low-income countries will bear the brunt of increased future demand for cancer surgery, bringing with it a need to substantially increase numbers of surgeons and anaesthetists,” Dr Perera said.

“These findings highlight a need to act quickly to ensure that increasing workforce requirements in low-income countries are adequately planned for.  There needs to be an increased focus on the application of cost-effective models of care, along with government endorsement of scientific evidence to mobilise resources for expanding services.

“In addition, access to post-operative care is strongly linked to lower mortality – so, improving care systems globally must be a priority in order to reduce the disproportionate number of deaths following complications.”

The researchers used best-practice guidelines, patient characteristics and cancer stage data to calculate the proportion of newly diagnosed cancer cases requiring surgery in 183 countries.

To predict future surgery demand, they applied these rates to GLOBACAN cancer incidence predictions from 2018 to 2040.

The study did not assess the impact of COVID-19, but the researchers acknowledge the delivery of high-quality post-operative care is more challenging during a pandemic.

Shortage of surgeons and anaesthetists

To deliver cancer surgery services optimally now and in future, the researchers also predicted requirements for surgical and anaesthesia workforces.

To evaluate current staffing gaps, they compared the optimal estimated workforce (the median workforce of 44 high-income countries) with the number of surgeons and anaesthetists in each country.

Dr Perera said there was a current global shortage of 199,000 surgeons and 87,000 anaesthetists.

“This is based on the current workforce of 766,000 surgeons and 372,000 anaesthetists, compared with 965,000 and 459,000 needed for an optimal workforce, respectively, in our modelling study,” he said.

“The gap is estimated to be greatest in low-income countries, where the current surgeon availability is 22,000 fewer than the model estimated optimal number of 28,000 surgeons.

“The current number of anaesthetists in low-income countries falls 11,000 below the model estimated demand of 13,000 anaesthetists.”

Optimal workforce estimates for 2040

In recognition of the rising global demand for cancer surgery, the researchers also calculated estimates for the optimal surgical and anaesthesia workforces needed in 2040.

Extrapolating 2018 data, taking account of the predicted future cancer incidence burden in each country, their findings revealed the surgical workforce will need to increase from 965,000 in 2018 to 1.416 million in 2040 (47% increase).

The anaesthetist workforce would need to rise from 459,000 in 2018 to 674,000 in 2040 (47% increase).

The researchers found the greatest relative increase in optimal workforce requirements from 2018 to 2040 would occur in low-income countries, where surgeon numbers are required to rise from 28,210 to 58,219 by 2040 (106%).

Anaesthetist numbers would also need to increase from 13,000 to 28,000 by 2040 (115%).

Dr Perera said “But to match the current benchmark of high-income countries, the actual number of surgeons in low-income countries would need to increase almost 400% (from 6,000 to 28,000), and anaesthetists by almost 550% (from 2000 to 13,000), of their baseline values.

“This is because the current workforce in low-income countries is already substantially smaller than in high-income countries.”

Potential limitations

Dr Perera said “We based predictions of future cancer rates on 2018 estimates, but country-level changes – such as economic developments or altered capacity to screen for early diagnosis – could impact cancer incidence and therefore surgical demand and workforce requirements.

“Furthermore, observed gaps in the workforce could also be narrower than the actual gaps in practice – our predictions were conservative because we only considered initial surgical encounters without accounting for follow-up interactions.”

The modelling study was an international collaboration between researchers from UNSW Sydney, University of Toronto, Kings College London, and the World Health Organisation (WHO).


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.